— Know what they know.
Not Investment Advice
Also trades as: 0M3O.L (LSE)

ZGNX NASDAQ

Zogenix, Inc.
1W: +2.2% 1M: +2.1% 3M: +114.0% 1Y: +28.6% 3Y: -47.6% 5Y: +169.5%
$26.68
Last traded 2022-03-04 — delisted
NASDAQ · Healthcare · Biotechnology

Revenue Segmentation

By Product / Service

By Geography

Income Trends

Revenue
$82M +498.8% ▲
5Y CAGR: +23.1%
Gross Profit
$77M +486.6% ▲
5Y CAGR: +64.5%
Operating Income
-$212M +14.4% ▲
Net Income
-$227M -8.6% ▼
EPS (Diluted)
$-4.24 -8.7% ▼
EBITDA
-$203M +6.9% ▲

Profit Margins

Year-over-Year Growth

View Full Income Statement
Line ItemFY2017FY2018FY2019FY2020FY2021
Revenue$10M$0$4M$14M$82M
YoY Growth-66.0%-100.0%+0.0%+274.0%+498.8%
Cost of Revenue$11M$0$0$542K$5M
Gross Profit-$908K$0$4M$13M$77M
Gross Margin-9.2%—100.0%96.0%94.1%
R&D Expenses$67M$101M$116M$138M$143M
SG&A Expenses$26M$39M$61M$100M$149M
Operating Expenses$93M$140M$176M$242M$299M
Operating Income-$120M-$141M-$430M-$248M-$212M
Operating Margin-1221.2%—-11782.4%-1815.7%-259.6%
Interest Expense$3M$6K$2K$4M$15M
Income Before Tax-$126M-$124M-$420M-$227M-$227M
Tax Expense-$3M$17M$0-$17M$105K
Net Income-$127M-$124M-$420M-$209M-$227M
Net Margin-1291.3%—-11499.5%-1534.7%-278.4%
EPS (Diluted)$-4.65$-3.27$-9.74$-3.90$-4.24
EBITDA-$124M-$124M-$418M-$218M-$203M
Shares Outstanding27M38M43M54M54M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms